Latest Breaking News On - Jinzi wu - Page 1 : vimarsana.com

Sagimet Biosciences Announces Appointment of Tim Walbert and Paul Hoelscher to its Board of Directors

SAN MATEO, Calif., March 25, 2024 Sagimet Biosciences Inc. , a clinical-stage biopharmaceutical company developing novel fatty acid synthase inhibitors designed to target dysfunctional.

Sagimet Biosciences Announces Appointment of Tim Walbert and Paul Hoelscher to its Board of ...

SAN MATEO, Calif., March 25, 2024 (GLOBE NEWSWIRE) Sagimet Biosciences Inc. (Sagimet, Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel fatty acid synthase (FASN) inhibitors designed to target dysfunctional

Gannex posts midphase data on NASH asset at center of trade secret row

Ascletis Pharma Announces IND Approval For ASC11 In China - Quick Facts

(RTTNews) - Ascletis Pharma Inc. (ASCLF.PK) said China National Medical Products Administration has approved the Investigational New Drug applicat.

Ascletis gets Chinese drug regulator nod to start trial of oral COVID therapy

Ascletis Pharma (ASCLF) said China's National Medical Products Administration ((NMPA)) approved its investigational new drug ((IND)) application for starting a trial of oral drug ASC11.

Ascletis is first Chinese biotech to get IND approvals for oral RdRp inhibitor

Ascletis investigational new drug application for a COVID-19 treatment has been approved by China's National Medical Products Administration.

China's first biotech to get IND approvals of an oral RdRp inhibitor

An investigational new drug application for a Covid-19 treatment has been approved by the China National Medical Products Administration.

Ascletis announces FDA clearance of drug for study of COVID-19 patients

A randomized, placebo-controlled study in mild to moderate COVID-19 patients has been approved by the US Food and Drug Administration (FDA).

Gannex doses first subject in Phase II primary biliary cholangitis trial

Gannex Pharma has dosed the first subject in Phase II trial of ASC42 for the treatment of primary biliary cholangitis (PBC) patients.

Ascletis expands ritonavir oral tablets production amid Covid-19 surge

Ascletis Pharma is expanding the production of rionavir oral tablets and the oral direct-acting antiviral R&D pipeline to treat Covid-19.